14.3 C
New York
Tuesday, March 21, 2023

The Question Is Whether To Buy Or Not To Buy Intercept Pharmaceuticals Inc. (NASDAQ: ICPT)

After Hours

It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Intercept Pharmaceuticals Inc. (ICPT) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.41, or -2.00%, to $20.07. The Intercept Pharmaceuticals Inc. has recorded 19,649 volume in the after hours trading session. Earlier, Yahoo Finance discussed this stock as it revealed Intercept Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates; Issues 2023 Financial Guidance.

From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio

The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.

Get our free report, "Top 5 AI Stocks to Buy for 2023".


Stocks Info

Intercept Pharmaceuticals Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $20.48 and fluctuated between $20.87 as its day high and $20.07 as its day low. The current market capitalization of Intercept Pharmaceuticals Inc. is $844.19M. A total of 0.71 million shares were traded on the day, compared to an average of 817.26K shares.

Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, ICPT has seen 7 BUY and 10 SELL insider trades, representing the acquisition of 123,800 and the disposition of 16,408 shares. Over the last 12 months, there were 13 BUYs and 23 SELLs from insiders. Insiders purchased 170,222 shares during that period but sold 31,732.

Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for ICPT in the last 3 months, the mean price target is $23.79 with high estimates of $49.00 and low estimates of $12.00. In terms of 52-week highs and lows, ICPT has a high of $21.86 and a low of $10.81.

As of this writing, ICPT has an earnings estimate of -$0.16 per share for the current quarter. EPS was calculated based on a consensus of 14 estimates, with a high estimate of $2.95 per share and a lower estimate of -$1.05. The company reported an EPS of -$0.25 in the last quarter, which was 49.00% higher than expectations of -$0.49.

Balance Sheet Annually/Quarterly

As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information.

Analysts Opinion

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 16 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ICPT is Underweight with a score of 3.58. A total of 3 analysts rated the stock as Buy while 2 rated it as Overweight while 9 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 1 thought it should be Sold.

Related Articles


Please enter your comment!
Please enter your name here

Latest Articles